@article{9ef28557b9da4aed833ccfa1daa6ba57,
title = "Selective activation, expansion, and monitoring of human iNKT cells with a monoclonal antibody specific for the TCR α-chain CDR3 loop",
abstract = "A significant fraction of CD1d-restricted T cells express an invariant T cell receptor (TCR) a-chain. These highly conserved invariant NKT (iNKT) populations are important regulators of a wide spectrum of immune responses. The ability to directly identify and manipulate iNKT cells is essential to understanding their function and to exploit their therapeutic potential. To this end, we sought monoclonal and polyclonal antibodies specific for iNKT cells by immunizing CD1d KO mice, which lack iNKT cells, with a cyclic peptide modeled after the TCRα CDR3 loop. One mAb (6B11) was specific for cloned and primary human but not rodent iNKT cells and the human invariant TCRα, as shown by transfection and reactivity with human invariant TCRα transgenic T cells ex vivo and in situ. 6B11 was utilized to identify, purify, and expand iNKT cells from an otherwise minor component of human peripheral blood lymphocytes and to specifically identify human iNKT cells in tissue. Thus, we report a novel and general strategy for the generation of mAb specific for the CDR3 loop encoded by the TCR of interest. Specifically, an anti-Vα24Jα18 CDR3 loop clonotypic TCR mAb is available for the enumeration and therapeutic manipulation of human and non-human primate iNKT populations. {\textcopyright} 2008 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.",
keywords = "Anti-TCR, Clonotypic, Cyclic peptide, IL-4, Invariant NKT",
author = "Exley, {Mark A.} and Runhua Hou and Angela Shaulov and Elena Tonti and Paolo Dellabona and Giulia Casorati and Omid Akbari and Akman, {H. Orhan} and Greenfield, {Edward A.} and Gumperz, {Jenny E.} and Boyson, {Jonathan E.} and Balk, {Steven P.} and Wilson, {S. Brian}",
note = "AI 42955, NIAID NIH HHS, United StatesAI 45051, NIAID NIH HHS, United StatesCA 89567, NCI NIH HHS, United StatesDK 066917, NIDDK NIH HHS, United StatesP20 RR021905-019004, NCRR NIH HHS, United StatesP20 RR021905-027752, NCRR NIH HHS, United StatesP20 RR021905-037042, NCRR NIH HHS, United StatesP20 RR021905-045989, NCRR NIH HHS, United StatesR01 AI060777, NIAID NIH HHS, United StatesR01 AI067897-01A2, NIAID NIH HHS, United StatesR01 AI067897-02, NIAID NIH HHS, United StatesR01 AI067897-03, NIAID NIH HHS, United StatesR01 DK066917, NIDDK NIH HHS, United StatesR01 DK066917-01, NIDDK NIH HHS, United StatesR01 DK066917-02, NIDDK NIH HHS, United StatesR01 DK066917-03, NIDDK NIH HHS, United StatesR01 DK066917-04, NIDDK NIH HHS, United StatesR01 DK066917-04S1, NIDDK NIH HHS, United StatesR01 DK066917-05, NIDDK NIH HHS, United StatesR01 HL071590, NHLBI NIH HHS, United StatesR21 CA089567, NCI NIH HHS, United StatesR21 CA089567-01, NCI NIH HHS, United StatesR21 CA089567-02, NCI NIH HHS, United StatesU19 046130-06, PHS HHS, United States",
year = "2008",
month = jun,
doi = "10.1002/eji.200737389",
language = "English",
volume = "38",
pages = "1756--1766",
journal = "European journal of immunology",
issn = "1521-4141",
publisher = "John Wiley & Sons Ltd",
number = "6",
}